WO2002072629A1 - Immunopotentiators - Google Patents
Immunopotentiators Download PDFInfo
- Publication number
- WO2002072629A1 WO2002072629A1 PCT/JP2002/002258 JP0202258W WO02072629A1 WO 2002072629 A1 WO2002072629 A1 WO 2002072629A1 JP 0202258 W JP0202258 W JP 0202258W WO 02072629 A1 WO02072629 A1 WO 02072629A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- serp
- glu
- amino acid
- peptide
- seq
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4732—Casein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to an immunopotentiator comprising a specific peptide.
- Milk itself is a nutrient source and is widely consumed.
- protein casein which is present in milk, has long been used as a protein source in infant formulas and special formulas, because of its good digestibility and the balance of essential amino acids consumed.
- Casein generally contains the amino acid residue phosphoserine, which has a phosphate group that is rarely found in normal proteins.
- a casein phosphopeptide (hereinafter sometimes abbreviated as “CPP”) is obtained by separating and purifying a fraction containing a large amount of phosphoserine residues from a casein digested with an enzyme.
- CPP is known to have the effect of maintaining the solubilized state of calcium insoluble in the small intestine and promoting the absorption of calcium, and has already been put to practical use as a raw material for many foods or feeds.
- CPPs are also known to enhance immunoglobulin A production in cultured cell lines or in the digestive tract of animals (see, for example, Milk Science vol. 49 (2000), pp. 73-79, and Food and Agricultural Immunolog y, 12 (2000), ppl65-173).
- CPP Since CPP is obtained by degrading casein with an enzyme, its antigenicity is lower than that of casein, but it has not completely disappeared. For this reason, there is a concern that those who are allergic to milk casein may cause an allergic reaction if they ingest CPP in order to enhance immunity.
- CPP is described, for example, in WO96 / 29340. Here, it is disclosed that CPP promotes mineral absorption in the small intestine, but there is no suggestion regarding immunological and potent activities. [Summary of Invention]
- the present inventors have now found that, among peptides derived from casein, those having a specific amino acid sequence having a plurality of phosphoserines exhibit an excellent immunopotentiating effect. Such a peptide exhibited an excellent immunopotentiating action even with a relatively small molecular weight.
- the present invention is based on such findings.
- an object of the present invention is to provide a peptide having a specific amino acid sequence and excellent in immunopotentiating activity, and an immunopotentiator comprising such a peptide.
- the immunopotentiator according to the present invention comprises a peptide having the following amino acid sequence (I).
- SerP represents a phosphoserine residue
- X represents any one to three amino acid residues
- the peptide according to the present invention has the following amino acid sequence (la).
- SerP represents a phosphoserine residue
- X represents 1-3 arbitrary amino acid residues
- Q 1 represents 0 to 14 arbitrary amino acid residues
- Q 2 represents any of 0 to 8 amino acid residues
- the peptide having the amino acid sequence (I) according to the present invention preferably has an immunopotentiating activity.
- the immunopotentiator according to the present invention can be used for mitogenic activity of spleen cells and immunoglobulin. It has an excellent immunostimulatory activity such as an activity to enhance the production of protein.
- the peptide having the amino acid sequence (I) contained in the immunostimulant of the present invention is a peptide containing a plurality of phosphoserine and having an immunopotentiating action of a small molecular weight. This is a distinctly different substance from CPP, which has been conventionally recognized as having an immunopotentiating activity and has a molecular weight of about 3000 to 5000.
- the peptide comprising the amino acid sequence (I) of the present invention has an excellent immunopotentiating effect, and at the same time, significantly reduces the milk allergic reaction caused by using casein or CPP. Or those that do not cause an allergic reaction. That is, the immunopotentiator according to the present invention is excellent in safety.
- the immunopotentiator according to the present invention is useful as a food material or a pharmaceutical ingredient that imparts an immunopotentiating effect to a person having a weak immune function.
- immunity enhancement can be expected by giving an infant with the immunopotentiator according to the present invention. Newborn infants are protected from infection by antibodies transferred from breast milk. Immunoglobulin A is mainly used as the transfer antibody in breast milk. Therefore, if a mother who cannot give breast milk gives the infant the immunopotentiator of the present invention, an effect equivalent to that of giving breast milk can be expected.
- the immunopotentiator according to the present invention can be composed of a peptide having a small molecular weight without antigenicity, it can be given to infants who are allergic to milk. Furthermore, even in an adult whose immunity has decreased due to aging, illness, fatigue, and the like, the use of the immunopotentiator of the present invention can safely promote daily health.
- FIG. 1 shows the results of examining the effects of the peptides (1) to (8) and the control on the proliferation activity of mouse spleen cells in Example 1 of Example.
- (1) to (8) represent the peptides (1) to (8) in Example 1, respectively.
- the superscript * indicates a statistically significant difference from the control, and the superscript ** indicates P ⁇ 0.01 and the superscript *** indicates P ⁇ 0.001.
- Fig. 2 shows the results of examining the effects of the peptides (1) to (8) and the control on immunoglobulin production in the mouse spleen cell culture system in Example 1 of the Example. The result is shown.
- (1) to (8) indicate the peptides (1) to (1) in Example 1.
- FIG. 3 shows the results of examining the effects of the peptides (8) to (11) and the control of (1) on the proliferation activity of spleen cells in mice in Example 1 of Example.
- (1) and (8) correspond to peptides (1) and
- FIG. 4 shows that, in Example 2 of the Example, the peptides (8) to (11) and the control (1) exerted an effect on the production of immunoglobulin (IgG + IgM + IgA) in a mouse spleen cell culture system.
- IgG + IgM + IgA immunoglobulin
- (1) and (8) denote peptides (1) and (8) in Example 1, respectively
- (9) to (11) denote peptides (9) to (11) in Example 2 respectively.
- the superscript * indicates a statistically significant difference from the control
- the superscript * indicates P ⁇ 0.05
- the superscript ** indicates P ⁇ 0.01, and the upper.
- FIG. 5 shows that in Examples 2 of the Examples, the peptides (8) to (11) and the control (1) were used in the mouse spleen cell culture system. 3 shows the results of examining the effect on immunoglobulin A production in E. coli.
- (1) and (8) are the peptides in Example 1.
- (1) and (8) are represented respectively, and (9) to (11) represent the peptides (9) to (11) in Example 2, respectively.
- the superscript * indicates a statistically significant difference from the control, and the superscript * indicates P ⁇ 0.05, and the superscript ** indicates P ⁇ 0.0.
- the immunopotentiator according to the present invention comprises a peptide consisting of an amino acid sequence containing at least a “SerP—X—SerP” sequence as a basic skeleton. Therefore, the present invention
- the immunopotentiator according to the present invention comprises a peptide having the following amino acid sequence (I). Q 1 -SerP- X -SerP- Q 2 (I)
- SerP represents a phosphoserine residue
- X represents one to three arbitrary amino acid residues
- 0 1 and 0 2 are either or both absent, or each independently represent one or more arbitrary amino acid residues.
- immune enhancer refers to an agent having immunopotentiating activity, and its use is not limited to pharmaceuticals, but may be for food, feed, and the like.
- "having an immunopotentiating activity” means that a mammal, particularly a human, can increase an immunopotentiating effect such as a spleen cell mitogenic activity and an immunoglobulin production enhancing activity.
- an immunopotentiating activity was significantly recognized by an index such as spleen fibrillation and an increase in the amount of immunoglobulin.
- amino acid includes optical isomers, that is, both D-form and L-form.
- amino acid as used herein means not only the 20 kinds of single amino acids that constitute a natural protein, but also other single amino acids, and / or other amino acids, such as 5-amino acids and non-natural amino acids. Etc. may be included.
- X in the amino acid sequence (I), X consists of one arbitrary amino acid residue.
- X in the amino acid sequence (I) consists of one arbitrary amino acid residue
- X is a group consisting of Leu, GlUs Ile, Thr, Ala, Arg, Lys ⁇ Asn, His, Val ⁇ and SerP.
- X is SerP or Leu, more preferably, X is SerP.
- the number of amino acid residues in Q1 is 1-201, more preferably 1-128, still more preferably 1-45, even more preferably 1-23, especially It is preferably 1 to 14.
- Q 2 represents one or more arbitrary amino acid residues.c
- the number of amino acid residues in Q 2 is 1 to 203, more preferably The number is preferably 1 to 192, more preferably 1 to 151, still more preferably 1 to 76, particularly preferably 1 to 31, and most preferably 1 to 11.
- the number of amino acid residues represented by Q 1 is 0 to 14, and the amino acid represented by Q 2
- the number of residues is 0-8. More preferably, Q1 has 0 to 8 amino acid residues, and Q2 has 0 to 5 amino acid residues. More preferably, Q1 has 0 to 1 amino acid residues, and Q2 has 0 to 2 amino acid residues.
- the number of amino acid residues of Q1 is 14 and the number of amino acid residues of Q2 is 8, except when the number is eight.
- SerP represents a phosphoserine residue
- X represents 1-3 arbitrary amino acid residues
- Q 1 represents 0 to 14 arbitrary amino acid residues
- Q 2 represents any of 0 to 8 amino acid residues
- This novel peptide can be the same as the peptide having the amino acid sequence (I) as long as it is included in the one represented by the formula (la).
- the amino acid residues represented by Q 1 and Q 2 do not exist. That is, the amino acid sequence (I) is preferably an oligopeptide consisting of “SerP—X—SerP”. No. When the number of amino acid residues in the amino acid sequence (I) is small as described above, no antigenicity is exhibited, and thus no allergic reaction is caused when an immunopotentiator is used. Therefore, a highly safe immunopotentiator can be obtained.
- amino acid sequence (I) is amino acid sequence (I)
- amino acid sequence (I) comprises:
- amino acid sequence (I) is:
- the amino acid sequence (I) is Arg-Glu-Leu-Glu-Glu-Leu-Asn-Val-Pro-Gly-Glu-Ile-Val-Glu-SerP- Leu-SerP ⁇ SerP-SerP-Glu-Glu-Ser-Ile-Thr-Y-Ile-Asn-Lys (SEQ ID NO: 11)
- Y is one arbitrary amino acid residue, preferably Arg or Cys, more preferably,
- a derivative of the peptide when referred to as a peptide, a derivative of the peptide is also included.
- the peptide derivative has the above-mentioned immunopotentiating activity, and has the basic skeleton sequence “SerP-X” in the peptide.
- the peptide according to the present invention comprises the amino acid sequence (I) as a repetitive sequence obtained by repeating at least twice.
- the number of repetitions of the amino acid sequence (I) in the peptide according to the present invention is at least 2 times, preferably 2 to 70 times, more preferably 2 to 30 times, still more preferably 2 to 10 times, More preferably, it is 2 to 4 times. From the viewpoint of exhibiting the above-mentioned effects more remarkably, the larger the number of repetitions, the better. However, the cost increases due to the complexity of the repetitive processing, and the safety or From the viewpoint of convenience and the like, the number of repetitions is preferably 2 to 10, more preferably 2 to 4.
- the number of amino acids constituting the peptide is as follows: The number is preferably 224 or less, more preferably 100 or less, and still more preferably 30 or less. Manufacturing method of peptide
- the peptides according to the present invention may be produced by utilizing various conventional synthetic methods or may be of natural origin. Since the amino acid sequence of the peptide according to the present invention has been determined, it may be obtained by synthesizing the entire amino acid sequence. It may be obtained by further synthesizing.
- the peptide of the present invention is obtained as a natural source, it can be obtained, for example, by the following procedure.
- casein for example, milk casein or yolk protein containing a protein containing a plurality of phosphoserine such as as 1-casein, hys 2 -casein, power zein, and fosvitin is prepared.
- CPP casein phosphopeptide
- ⁇ -Casein is hydrolyzed with crystalline tribcine to form CPP, and then unreacted casein and some impurities are precipitated and removed at pH 4.7, and barium chloride and ethanol (final) are added to the supernatant. 50% (v / v)) to recover CPP as a precipitate (e.g., RFPeterson, LW Norman and TL cMeekin, Journal of the American Chemical Society, 80, pp95-99 (1958)),
- Casein is hydrolyzed by trypsin at a predetermined temperature and pH conditions (for example, pH 7.0-8.5s 50 ° C) to generate CPP, and then, at around pH 5, unrestressed zein After removing some impurities by precipitation, CPP is precipitated and recovered by adding calcium salt or calcium acetate and an organic solvent such as ethanol to the supernatant (Japanese Patent Publication No. 2-76166) ).
- the CPP obtained as described above is required for endoproteases such as trypsin and chymotrypsin, and various beptose enzymes such as aminopeptidase and carboxypeptidase. Is processed using the combination of As a result, a peptide according to the present invention having a desired length depending on the application can be obtained.
- the resulting phosphopeptide is reacted with an enzyme selected from the group consisting of aminopeptidylase, carboxypeptidylase, and a combination thereof to obtain the above-mentioned peptide.
- a method comprising:
- the peptide according to the present invention is obtained by utilizing various conventional synthesis methods, it can be obtained, for example, by the following procedure.
- the peptide according to the present invention can be obtained by a conventional method, for example, a method according to Paquet et al. (A. Paquet and M. Johns, Int. J. Pept Protein Res, 36 (2), pp97-103, (1990)). It can be prepared by applying an ordinary peptide synthesis method.
- a specific example first, phosphoserine in which an amino acid is protected with a t-butoxycarbonyl group (Boc) or the like and various amino acids are subjected to a stepwise activating method or a condensation method, which is a conventional method for the synthesis of peptides.
- a phosphopeptide containing a phosphoserine group at an arbitrary position can be prepared. This method can be carried out by a liquid phase method or a solid phase method.
- the immunopotentiator according to the present invention can be used for a drug, food or feed.
- an immunopotentiator used as a medicament. More preferably, the immunopotentiator is used as a medicament for enhancing immunoglobulin production.
- the immunopotentiator When the immunopotentiator according to the present invention is used as a medicament, the immunopotentiator can be prepared in an appropriate dosage form depending on the administration route. Specifically, injections such as intravenous injections and intramuscular injections, capsules, wraps, drops, tablets, granules, powders, pills, fine granules, dragees, lozenges, troches and the like, and rectal administration And lipophilic suppositories can be prepared.
- the immunopotentiator may be in the form of a liquid or a liquid-encapsulated capsule, if necessary.
- formulations contain commonly used excipients, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, dispersants, buffers, preservatives, solubilizers, preservatives, It can be produced in a usual manner by further using pharmaceutically acceptable additives for pharmaceutical preparations such as a flavoring agent, a soothing agent, a stabilizer and the like. That is, the immunopotentiator according to the present invention may further comprise a pharmaceutically acceptable additive for a pharmaceutical preparation.
- Pharmaceutical additives that can be used include, for example, lactose, fructose, glucose, starch, gelatin, magnesium carbonate, synthetic magnesium silicate, talc, magnesium stearate, methylcellulose or salts thereof, gum arabic, polyethylene glycol, syrup Oral, petrolatum, glycerin, ethanol, propylene glycol, citric acid, sodium chloride, sodium sulfite, sodium phosphate and the like.
- the administration form of the immunopotentiator can adopt various forms such as oral administration, parenteral administration, inhalation, rectal administration and topical administration.
- parenteral administration includes subcutaneous injection, intravenous administration, intramuscular administration, intranasal administration or infusion. Therefore, for example, mucosal administration such as nose, buccal cavity, sublingual, rectal, etc., or transdermal administration, or administration using an implant may be used. And patients selected from the group consisting of non-human animals
- the dose is appropriately determined in consideration of the usage, the age of the patient, the sex, the degree of the symptoms, and the like. However, in terms of the amount of the peptide in the immunopotentiator, it is usually about 10 to 100 per adult per day. 0 mg ⁇ Preferably, the dose is 50 to 50 mg, which can be administered once or several times a day.
- the immunopotentiator according to the present invention thus provided in the form of a medicine can be advantageously used in the treatment or prevention of various infectious diseases, and in the treatment of diseases such as allergic diseases and autoimmune diseases. it can.
- secreted IgA an immunoglobulin secreted into milk, inhibits the binding of strong pathogenic microorganisms to the intestinal mucosa and inactivates its action by specifically binding to bacterial toxins. It is known that it binds to a dietary antigen acting as an allergen and prevents it from passing through the digestive tract wall to suppress allergic reactions.
- IgG antibodies to dietary antigens appear frequently and allergic diseases And the occurrence frequency of autoimmune diseases is known to be high.
- the immunopotentiator of this invention since the induction
- the immunopotentiator When the immunopotentiator according to the present invention is used as a food, the immunopotentiator may be provided in the form of gum, biscuit, chocolate, candy, jelly, tablet, confection, milk powder, and beverage.
- the provision of the immunopotentiator according to the present invention in the form of a food is It is effective for nutritional supplementation and health promotion of inferior young and elderly people, patients after illness, etc., and also for health improvement of patients with diseases such as allergic diseases.
- the immunopotentiator When the immunopotentiator according to the present invention is used as a feed, the immunopotentiator is provided in the form of feed for livestock such as feed for dairy cattle, feed for pigs, feed for poultry, pet food, various compound feeds and the like. May be done.
- livestock such as feed for dairy cattle, feed for pigs, feed for poultry, pet food, various compound feeds and the like. May be done.
- the amount of feed is determined as appropriate in consideration of the type, age, weight, sex, feeding environment, etc. of livestock animals, but the amount of the immunopotentiator component as feed is 0 to the total amount of feed to be fed. It is preferably contained in an amount of 0.1 to 1% by weight, more preferably 0.05 to 0.5% by weight. It is preferable to supply this to a domestic animal such as a baby for a fixed period of time, preferably for 3 weeks or more, more preferably for about 5 weeks.
- the immunopotentiator according to the present invention which is provided in the form of feed, can easily enhance the immunity of livestock animals. Therefore, for example, infectious diseases and allergic reactions of livestock animals such as cattle on ranches and the like are possible. It can treat and prevent diseases and the like.
- the immunopotentiator according to the present invention as a feed, it is possible to reduce the amount of use and increase the ratio of other feed components as compared with a feed using CPP, according to another aspect of the present invention.
- a method for enhancing immunity of a patient having reduced or weak immunity comprising administering the peptide according to the present invention to a patient having reduced or weak immunity.
- Example 1
- phosphopeptides Based on the amino acid sequence of the obtained phosphopeptide, five types of synthetic phosphopeptides corresponding to the partial structure thereof, such as the following peptides (3) to (7), were synthesized. These phosphopeptides were synthesized by a solid phase synthesis method using Fmoc amino acids. Specifically, these were synthesized by sequentially attaching a high amino acid whose side chain was protected to a resin. At this time, an Fmoc group (9-Fluorenylmethoxycarbonyl group), which can be removed with a strong base, was used as the amino acid protecting group. After removing this protecting group, the next amino acid was bound using a binder. The peptide thus obtained was cleaved from the resin with a strong acid, and at the same time, the protecting group of the side chain was removed. Thereafter, the obtained crude peptide was purified by HPLC to obtain the target synthetic peptide .
- Fmoc group 9-Fluorenylmeth
- Peptide (7) was obtained from Biologica Co., Ltd., and Peptides (3) to (6) were obtained from Vex Inc., each of which was commissioned for synthesis. These were each 80% pure and had a peptide content of 1 Omg.
- a peptide consisting only of phosphoserine (peptide (2)), a control containing no amino acid or peptide (peptide (1)), and 1 to 28 And casein phosphopeptide (peptide (8)).
- the peptides (1) to (8) obtained above were subjected to the following evaluation tests to evaluate the immunopotentiating ability of each peptide.
- Mouse spleen cells used in the test were aseptically collected from 6-week-old male C3H / HeN mice. This was cultured in Celgrosser-P medium containing 10 OU / ml of penicillin and 10 ⁇ g / ml of streptomycin.
- each peptide as the sample described above was added to a concentration of 2 nM, and 0.5 ⁇ g of concanavalin (ConA), Magglutinin (PHA) or 50 g of lipopolysaccharide (LPS) was added to 5 g of the phytofat, and they were cultured under 37 ° C. and 5% CO 2.
- ConA concanavalin
- PHS lipopolysaccharide
- Test 1 A Cell proliferation activity
- the proliferation activity of the cells was evaluated by the number of cells after 48 hours.
- Test 1B Immunoglobulin production
- Immunoglobulin production was measured at 72-120 hours of culture.
- the amount of immunoglobulin A was measured by a sandwich ELISA method (Williams, DJL et al., Vet. Immunol. Immunopath., 24 (1990), pp267-283). You That is, a cell culture solution is added to a plate coated with anti-mouse immunoglobulin A from Bhutan, washed, and reacted with anti-mouse immunoglobulin 8 from sheep labeled with horseradish peroxidase. Determined by
- the peptides (9) to (11) were obtained from Vex Inc. by outsourcing their synthesis. These were each 80% pure and the amount of peptide was 1 Omg. In addition to these synthetic peptides (9) to (11), a control (peptide (1)) to which no amino acid or peptide was added and a casein phosphopeptide (peptide (8)) comprising 1 to 28 regions were used. Was prepared. Evaluation test 2:
- the peptides (9) to (11), and the peptides (1) and (8) obtained above were subjected to the following evaluation test to evaluate the immunopotentiating ability of each peptide.
- mice spleen cells used in the test were prepared and cultured in the same manner as in Example 1 above.
- the growth promoting activity of spleen cells in mice was evaluated in the same manner as in Example 1 above.
- the cell proliferation number was determined from the MTT value based on the absorbance at 570 nm, as in Example 1 above.
- Immunoglobulin production was measured at 72-120 hours of culture.
- the amount of immunoglobulin was measured by the sandwich ELI SA method (Williams, D.J.L. et al., Vet. Immunol. Cell Biol., 74 (1990). Pp323-329). That is, a cell culture solution was added to a plate coated with goat anti-mouse immunoglobulin (IgG + IgM + IgA or IgA), washed, and labeled with horseradish peroxidase. The anti-mouse immunoglobulin antibody of IgG (IgG + IgM + IgA) or the same sheep anti-mouse immunoglobulin antibody A was used for the reaction. The results were as shown in FIGS.
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002439236A CA2439236A1 (en) | 2001-03-09 | 2002-03-11 | Immuno-enhancing agent |
KR10-2003-7011284A KR20040008130A (ko) | 2001-03-09 | 2002-03-11 | 면역 증강제 |
EP02702879A EP1375513A4 (en) | 2001-03-09 | 2002-03-11 | IMMUNOSTIMULANTS |
JP2002571542A JPWO2002072629A1 (ja) | 2001-03-09 | 2002-03-11 | 免疫増強剤 |
US10/471,177 US20050220801A1 (en) | 2001-03-09 | 2002-03-11 | Immunopotentiators |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001067600 | 2001-03-09 | ||
JP2001-67600 | 2001-03-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002072629A1 true WO2002072629A1 (en) | 2002-09-19 |
Family
ID=18925926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/002258 WO2002072629A1 (en) | 2001-03-09 | 2002-03-11 | Immunopotentiators |
Country Status (7)
Country | Link |
---|---|
US (1) | US20050220801A1 (ja) |
EP (1) | EP1375513A4 (ja) |
JP (1) | JPWO2002072629A1 (ja) |
KR (1) | KR20040008130A (ja) |
CN (1) | CN1496368A (ja) |
CA (1) | CA2439236A1 (ja) |
WO (1) | WO2002072629A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015516377A (ja) * | 2012-03-19 | 2015-06-11 | ミレウティス リミテッド. | 乳汁分泌の管理用のペプチド |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012200889B2 (en) * | 2005-05-02 | 2014-05-15 | Mileutis Ltd. | Pharmaceutical compositions comprising casein derived peptides and methods of use thereof |
ZA200710374B (en) * | 2005-05-02 | 2009-06-24 | Mileutis Ltd | Pharmaceutical compositions comprising casein derived peptides and methods of use thereof |
EP1890720B1 (en) * | 2005-05-02 | 2013-01-09 | Mileutis Ltd. | Pharmaceutical compositions comprising casein derived peptides and methods of use thereof |
BE1017094A3 (nl) | 2006-04-05 | 2008-02-05 | Wiele Michel Van De Nv | Werkwijze voor het weven van poolweefsels met variabele poolhoogte. |
CN110483622B (zh) * | 2019-08-26 | 2021-06-11 | 无限极(中国)有限公司 | 酪蛋白磷酸肽及其制备方法、应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07502020A (ja) * | 1991-08-22 | 1995-03-02 | ザ ユニヴァーシティ オブ メルボルン | 歯石処理用ホスホペプチド |
WO1997046099A1 (en) * | 1996-06-06 | 1997-12-11 | Neorx Corporation | Liver retention clearing agents |
-
2002
- 2002-03-11 KR KR10-2003-7011284A patent/KR20040008130A/ko not_active Application Discontinuation
- 2002-03-11 US US10/471,177 patent/US20050220801A1/en not_active Abandoned
- 2002-03-11 CN CNA028061969A patent/CN1496368A/zh active Pending
- 2002-03-11 WO PCT/JP2002/002258 patent/WO2002072629A1/ja not_active Application Discontinuation
- 2002-03-11 CA CA002439236A patent/CA2439236A1/en not_active Abandoned
- 2002-03-11 JP JP2002571542A patent/JPWO2002072629A1/ja not_active Withdrawn
- 2002-03-11 EP EP02702879A patent/EP1375513A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07502020A (ja) * | 1991-08-22 | 1995-03-02 | ザ ユニヴァーシティ オブ メルボルン | 歯石処理用ホスホペプチド |
WO1997046099A1 (en) * | 1996-06-06 | 1997-12-11 | Neorx Corporation | Liver retention clearing agents |
Non-Patent Citations (7)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015516377A (ja) * | 2012-03-19 | 2015-06-11 | ミレウティス リミテッド. | 乳汁分泌の管理用のペプチド |
Also Published As
Publication number | Publication date |
---|---|
US20050220801A1 (en) | 2005-10-06 |
EP1375513A1 (en) | 2004-01-02 |
JPWO2002072629A1 (ja) | 2004-07-02 |
CA2439236A1 (en) | 2002-09-19 |
EP1375513A4 (en) | 2006-04-12 |
KR20040008130A (ko) | 2004-01-28 |
CN1496368A (zh) | 2004-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kitts et al. | Bioactive proteins and peptides from food sources. Applications of bioprocesses used in isolation and recovery | |
CA2266859C (en) | Colostrinin, and uses thereof | |
JP3128244B2 (ja) | カゼインホスホペプチド、これを含むカゼイン及びこれらの製造方法 | |
Bhat et al. | Bioactive peptides from egg: a review | |
US20100167979A1 (en) | Rheumatoid arthritis-preventive agent for oral intake | |
JP2805194B2 (ja) | 血中トリグリセリド濃度上昇抑制ペプチド及び当該ペプチドを有効成分として含む血中トリグリセリド濃度上昇抑制剤 | |
AU5076099A (en) | Peptides based on the sequence of human lactoferrin and their use | |
KR0161747B1 (ko) | 지방세포 분화 억제 펩타이드 및 그를 유효성분으로 포함하는 지방세포 분화 억제제 | |
CN110381964A (zh) | Glp-1分泌促进剂和组合物 | |
WO2002072629A1 (en) | Immunopotentiators | |
JP2800877B2 (ja) | 血中トリグリセリド濃度上昇抑制ペプチド及び当該ペプチドを有効成分として含む血中トリグリセリド濃度上昇抑制剤 | |
JP2005263782A (ja) | ローヤルゼリー由来の抗酸化性ペプチド | |
JP2004010569A (ja) | コレシシトキニン分泌促進活性を有するアルギニン含有ペプチドおよびこれを含有する食品。 | |
JP2863898B2 (ja) | 新規なペプチドおよび免疫賦活剤 | |
US20040171553A1 (en) | Peptides fragments of colostrinin and their use | |
KR100262468B1 (ko) | 혈중 트리글리세리드의 농도상승을 억제하는 펩티드 및 활성성분으로서 펩티드를 함유한 혈중 트리글리세리드의 농도상승 억제제 | |
JP2873434B2 (ja) | 新規なペプチドおよび免疫賦活剤 | |
JPH07138187A (ja) | 経口免疫寛容原、経口慢性関節リウマチ治療剤及び機能性食品 | |
JP2004099457A (ja) | 抗アレルギー材 | |
JP2004043326A (ja) | 免疫増強剤 | |
AU761148B2 (en) | Colostrinin, and uses thereof | |
JPH07138287A (ja) | 新規なペプチドおよび免疫賦活剤 | |
GB2352176A (en) | Colostrinin and uses thereof | |
JP2002265496A (ja) | 新規なテトラペプチドおよび免疫賦活剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002236288 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2439236 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037011284 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 527938 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002571542 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 028061969 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10471177 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002702879 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002702879 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037011284 Country of ref document: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002702879 Country of ref document: EP |